Skip to main content
. 2023 Aug 31;137(16):1333–1346. doi: 10.1042/CS20230586

Figure 2. Major pathophysiological parameters at baseline, at the Clinical End Point of HbA1c <48mmol/mol (CEP) and at 12 months.

Figure 2

Median (IQR) liver fat, very low-density lipoprotein-1 (VLDL) triglyceride, plasma triglycerides with palmitic acid content reflecting rate of de novo lipogenesis, total plasma triglyceride, and Disposition Index at baseline, the co-primary end points of CEP (clinical end point; HbA1c <48 mmol/mol) and at 12 months in the T2D group. Numbers of participants and level of statistical significance vs. baseline are shown below CEP and 12 months. Non-diabetic control data are also shown with the level of significance vs. T2D at 12 months below ‘Control’.